Literature DB >> 8383984

Opioid receptors in midbrain dopaminergic regions of the rat. I. Mu receptor autoradiography.

D C German1, S G Speciale, K F Manaye, M Sadeq.   

Abstract

Several lines of evidence indicate that an interaction exists between opioid peptides and midbrain dopaminergic neurons. The purpose of this study was to map and quantify the density of the mu opioid receptor subtype relative to the location of the dopaminergic (DA) neurons in the retrorubral field (nucleus A8), substantia nigra (nucleus A9), and ventral tegmental area and related nuclei (nucleus A10) in the rat. Sections through the rostral-caudal extent of the midbrain were stained with an antibody against tyrosine hydroxylase, as a DA cell marker, and comparable sections were processed for in vitro receptor autoradiography using the mu-selective ligand, 3H-Tyr-D-Ala-N-MePhe-Gyl-ol enkephalin. In the nucleus A8 region, there were low levels of mu binding. In the rostral portion of nucleus A9, there was prominent mu binding both in the ventral pars compacta, which contains numerous DA neurons, and in regions that correspond to the location of the DA dendrites which project ventrally into the underlying substantia nigra pars reticulata. In the caudal portion of nucleus A9, mu binding was greatest in the substantia nigra pars reticulata, but also in the same region that contains DA neurons. In nucleus A10, mu receptor densities differed depending upon the nucleus A10 subdivision, and the rostral-caudal position in the nucleus. Low receptor densities were observed in rostral portions of the ventral tegmental area and interfascicular nucleus, and there was negligible binding in the parabrachial pigmented nucleus and paranigral nucleus at the level of the interpeduncular nucleus; all regions where there are high densities of DA somata. Mu binding was relatively high in the central linear nucleus, and in the dorsal and medial divisions of the medial terminal nucleus of the accessory optic system, which has been shown to contain DA dendrites. These data indicate that mu opioid receptors are located in certain regions occupied by all three midbrain DA nuclei, but in a highly heterogeneous fashion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383984     DOI: 10.1007/bf01244917

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  31 in total

1.  ACTH1-39 inputs to mesocorticolimbic dopaminergic neurons: light and electron microscopic examination.

Authors:  C L Liang; G P Kozlowski; S A Joseph; D C German
Journal:  Neurosci Lett       Date:  1992-10-26       Impact factor: 3.046

2.  Multiple opiate receptors: different regional distribution in the brain and differential binding of opiates and opioid peptides.

Authors:  K J Chang; B R Cooper; E Hazum; P Cuatrecasas
Journal:  Mol Pharmacol       Date:  1979-07       Impact factor: 4.436

3.  Autoradiographic localization of mu- and delta-opiate receptors in the forebrain of the rat.

Authors:  S McLean; R B Rothman; M Herkenham
Journal:  Brain Res       Date:  1986-07-16       Impact factor: 3.252

4.  Catecholamine biosynthesis in brains of rats treated with morphine.

Authors:  D H Clouet; M Ratner
Journal:  Science       Date:  1970-05-15       Impact factor: 47.728

5.  Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat.

Authors:  D C German; K F Manaye
Journal:  J Comp Neurol       Date:  1993-05-15       Impact factor: 3.215

6.  Localization of opiate receptors in substantia nigra evidence by lesion studies.

Authors:  C Llorens-Cortes; H Pollard; J C Schwartz
Journal:  Neurosci Lett       Date:  1979-05       Impact factor: 3.046

7.  Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids.

Authors:  M G Lacey; N B Mercuri; R A North
Journal:  J Neurosci       Date:  1989-04       Impact factor: 6.167

8.  Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine.

Authors:  R T Matthews; D C German
Journal:  Neuroscience       Date:  1984-03       Impact factor: 3.590

9.  Striatal opiate mu-receptors are not located on dopamine nerve endings in the rat.

Authors:  F Trovero; D Herve; M Desban; J Glowinski; J P Tassin
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

10.  Quantitative film autoradiography of opiate agonist and antagonist binding in rat brain.

Authors:  W A Geary; G F Wooten
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

View more
  6 in total

1.  The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse.

Authors:  J L Rogers; S Ghee; R E See
Journal:  Neuroscience       Date:  2007-10-22       Impact factor: 3.590

Review 2.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

3.  Opioid receptors in midbrain dopaminergic regions of the rat. II. Kappa and delta receptor autoradiography.

Authors:  S G Speciale; K F Manaye; M Sadeq; D C German
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  Systemic morphine-induced Fos protein in the rat striatum and nucleus accumbens is regulated by mu opioid receptors in the substantia nigra and ventral tegmental area.

Authors:  B Bontempi; F R Sharp
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

Review 5.  Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Authors:  Malú G Tansey; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

6.  Morphine induces c-fos and junB in striatum and nucleus accumbens via D1 and N-methyl-D-aspartate receptors.

Authors:  J Liu; J Nickolenko; F R Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.